CTOs on the Move

Sengenics

www.sengenics.com

 
Sengenics is a functional proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ was invented and patented by Professor Jonathan Blackburn whilst he was a member of the faculty at the University of Cambridge. Jonathan is the CSO of Sengenics. The key application of KREX™ is the discovery of autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX™ can also be used to identify autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions years ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

BioStar Systems

BioStar Systems is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Polyplus Transfection

Polyplus Transfection is a San Marcos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bryan LGH

Bryan LGH is a Lincoln, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Advaxis

Advaxis, Inc., a clinical development stage biotechnology company, focuses on developing immunotherapies for cancer and infectious diseases. Its Lm -LLO immunotherapy platform technology stimulates the immune system to induce antigen-specific anti-tumor immune responses involving innate and adaptive arms of the immune system by inhibiting the T-cells, Tregs, myeloid-derived suppressor cells, and MDSC to promote immunologic tolerance of cancer cells in the tumor. The company’s platform technology also facilitates the immune response by altering the tumor microenvironment to reduce immunologic tolerance in the tumors that makes the tumor more susceptible to immune attack. It has approximately 15 distinct immunotherapies in various stages of development, directly developed by the company and through strategic collaborations. The company’s products in clinical development stage comprise ADXS-HPV that is being evaluated in various clinical trials for cervical cancer, head and neck cancer, and anal cancer; ADXS-PSA for the treatment of prostate cancer; and ADXS-cHER2 for the treatment of overexpressing cancers, such as breast, gastric, and other cancers in humans, as well as for osteosarcoma in canines. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Zija International

Zija International is a Lindon, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.